PLM-101
Product Specifications
Target
Others|||FLT|||c-RET
Related Pathways
Angiogenesis|||Tyrosine Kinase/Adaptors|||Others|||Apoptosis
Bioactivity
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET. It impedes RET function, promoting autophagic breakdown of FLT3, and suppresses the PI3K and Ras/ERK pathways, contributing to its anti-leukemic effects. The compound's antitumor efficacy is demonstrated in both a mouse MV4-11 flank xenograft model (doses of 3 and 10 mg/kg; po) and an allogeneic xenograft mouse model (dose of 40 mg/kg; po) [1].
Molecular Formula
C22H22FN5O2
Molecular Weight
407.44
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Product Datasheet
https://www.targetmol.com/attachment/DataSheet/123792051975225546/T78871
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
